Barclays PLC Buys 20,777 Shares of Agenus Inc. (NASDAQ:AGEN)

Barclays PLC raised its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 295.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,813 shares of the biotechnology company’s stock after acquiring an additional 20,777 shares during the quarter. Barclays PLC owned approximately 0.12% of Agenus worth $152,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in shares of Agenus in the 2nd quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus in the 2nd quarter worth $106,000. EP Wealth Advisors LLC purchased a new position in Agenus in the 3rd quarter worth $55,000. HighTower Advisors LLC raised its stake in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. Finally, Blair William & Co. IL purchased a new position in Agenus in the 2nd quarter worth $441,000. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Down 4.4 %

Shares of NASDAQ:AGEN opened at $3.66 on Thursday. The company has a market cap of $85.86 million, a P/E ratio of -0.33 and a beta of 1.27. Agenus Inc. has a 52 week low of $2.50 and a 52 week high of $19.69. The company has a 50-day moving average price of $3.14 and a 200 day moving average price of $5.03.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Wednesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.